Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
This trial is active, not recruiting.
|Condition||nasopharyngeal carriage of s. pneumoniae|
|Sponsor||Boston Medical Center|
|Collaborator||Thrasher Research Fund|
|Start date||April 2010|
|End date||October 2012|
|Trial size||5000 participants|
|Trial identifier||NCT01109108, H-28757|
The specific aim is to evaluate the impact of PCV13 as administered in the pediatric primary care clinic at Boston medical center on the serotype specific carriage of Streptococcus pneumoniae in children < 5 and their parents.
Specifically the investigators will measure the decline in vaccine serotypes, the proportion of children receiving vaccine required to achieve 50% reduction in serotype specific carriage and the correlation between immunogenicity of the specific serotypes and decline in carriage.
children less than 2 years of age
children 2-5 years of age
parents of children
serotype specific colonization with S. pneumoniae
time frame: 2 years
Male or female participants of any age.
Inclusion Criteria: - children < 5 years of age receiving care at Primary Care center at BMC and as many parent(s) as willing to participate Exclusion Criteria: - children with facial malformations making NP sampling unacceptable
|Official title||Streptococcus Pneumonia: Herd Effects and Emergence of Potentially Virulent Serotypes PCV13_Impact of NP Colonization, Herd Effects and Emergence of Potentially Virulent Serotypes of Pneumococci|
Call for more information